How a new generation of coronary sinus reducer can significantly expand treatment options for patients with coronary microvascular dysfunction
Sponsored by VahatiCor
Other coronary interventions
Symposium
VahatiCor
Room 243
Anchorperson: Bruce Samuels
Spokesperson: William Wijns
Discussants: Bernard De Bruyne, Francesco Giannini, Alexandra Lansky, Tim Van De Hoef
Chatmaster: Samit Shah
Watch this session if you want
- To understand the Reducer therapy mechanism of action for coronary microvascular dysfunction
- To know the plans of VahatiCor’s for building clinical evidence in coronary microvascular dysfunction
- To understand AFLUX’s design to simplify the procedure and increase response rate
- To recognise the importance of diagnosing coronary microvascular dysfunction
Welcome and session objectives
Bruce Samuels
Diagnosing a coronary microvascular dysfunction patient
Bernard De Bruyne
Discussion and audience interaction
Coronary microvascular dysfunction patient case
Francesco Giannini
Discussion and audience interaction
Coronary sinus reducer and mechanism of action in coronary microvascular dysfunction
Tim Van De Hoef
Discussion and audience interaction
Clinical path SERRA - Early feasibility study
Alexandra Lansky
Discussion and audience interaction
Session evaluation and key learnings
Bruce Samuels
